A Single Immunization with CoVaccine HT-Adjuvanted H5N1 Influenza Virus Vaccine Induces Protective Cellular and Humoral Immune Responses in Ferrets
- 15 August 2010
- journal article
- research article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 84 (16) , 7943-7952
- https://doi.org/10.1128/jvi.00549-10
Abstract
Highly pathogenic avian influenza A viruses of the H5N1 subtype continue to circulate in poultry, and zoonotic transmissions are reported frequently. Since a pandemic caused by these highly pathogenic viruses is still feared, there is interest in the development of influenza A/H5N1 virus vaccines that can protect humans against infection, preferably after a single vaccination with a low dose of antigen. Here we describe the induction of humoral and cellular immune responses in ferrets after vaccination with a cell culture-derived whole inactivated influenza A virus vaccine in combination with the novel adjuvant CoVaccine HT. The addition of CoVaccine HT to the influenza A virus vaccine increased antibody responses to homologous and heterologous influenza A/H5N1 viruses and increased virus-specific cell-mediated immune responses. Ferrets vaccinated once with a whole-virus equivalent of 3.8 μg hemagglutinin (HA) and CoVaccine HT were protected against homologous challenge infection with influenza virus A/VN/1194/04. Furthermore, ferrets vaccinated once with the same vaccine/adjuvant combination were partially protected against infection with a heterologous virus derived from clade 2.1 of H5N1 influenza viruses. Thus, the use of the novel adjuvant CoVaccine HT with cell culture-derived inactivated influenza A/H5N1 virus antigen is a promising and dose-sparing vaccine approach warranting further clinical evaluation.Keywords
This publication has 44 references indexed in Scilit:
- A Single-Dose Influenza A (H5N1) Vaccine Safe and Immunogenic in Adult and Elderly Patients: an Approach to Pandemic Vaccine DevelopmentJournal of Virology, 2010
- The Severity of Pandemic H1N1 Influenza in the United States, from April to July 2009: A Bayesian AnalysisPLoS Medicine, 2009
- The novel adjuvant CoVaccineHT™ increases the immunogenicity of cell-culture derived influenza A/H5N1 vaccine and induces the maturation of murine and human dendritic cells in vitroVaccine, 2009
- Evaluation of Vaccines for H5N1 Influenza Virus in Ferrets Reveals the Potential for Protective Single-Shot ImmunizationJournal of Virology, 2009
- Safety and Immunogenicity of an Inactivated Influenza A/H5N1 Vaccine Given with or without Aluminum Hydroxide to Healthy Adults: Results of a Phase I–II Randomized Clinical TrialThe Journal of Infectious Diseases, 2008
- Screening monoclonal antibodies for cross-reactivity in the ferret model of influenza infectionJournal of Immunological Methods, 2008
- Cross-Protection against Lethal H5N1 Challenge in Ferrets with an Adjuvanted Pandemic Influenza VaccinePLOS ONE, 2008
- Cross‐Reactivity to Highly Pathogenic Avian Influenza H5N1 Viruses after Vaccination with Nonadjuvanted and MF59‐Adjuvanted Influenza A/Duck/Singapore/97 (H5N3) Vaccine: A Potential Priming StrategyThe Journal of Infectious Diseases, 2005
- Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenzaThe Lancet, 2001
- Beitrag zur kollektiven Behandlung pharmakologischer ReihenversucheNaunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie, 1931